J&J Interested In ‘Differentiated’ Obesity Assets

“It would be an area of interest to us,” Johnson & Johnson CEO Joaquin Duato said of the obesity space during the Morgan Stanley Healthcare Conference.

J&J building
Johnson & Johnson CEO Duato discussed M&A strategy • Source: Shutterstock

Johnson & Johnson is not ruling out being a late entrant into the obesity space. During an appearance at the Morgan Stanley Healthcare Conference on 4 September, CEO Joaquin Duato said the company is interested in obesity – but it would have to develop a differentiated product.

Key Takeaways
  • J&J CEO Joaquin Duato discussed M&A strategy during the Morgan Stanley Healthcare Conference.

“If we were able to identify assets in obesity that were sufficiently differentiated, it would be an area of interest...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Alimentary/Metabolic

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By 

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By 

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By 

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

More from Therapy Areas

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By 

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.